Single Dose Escalations Study of Amphotericin B Colloidal Dispersion In Healthy Subjects in China

Inclusion Criteria: * Body mass index (BMI) of 19 to 26 kg/m2, inclusive 19 and 26. BMI = weight (kg)/\[height(m)\]2. * Subjects are fully informed and voluntarily consent to participate in this study. Exclusion Criteria: * History of allergy or hypersensitivity. * Presence of any acute or chronic medical condition within 3 months prior to investigational products administration, including but not limited to: hepatic, gastrointestinal, renal, hematologic (including coagulation), pulmonary, neurologic, respiratory, endocrine, or cardiovascular system abnormalities; psychiatrical disease including major psychiatric disorders (e.g., schizophrenia, bipolar disorder); acute infection; or other conditions that would interfere with the absorption, distribution, metabolism, or excretion of drugs. * During the screening period, abnormal and clinically significant of physical examination, vital signs, laboratory examination, etc. * A positive result in hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test. * Lost blood or donated more than 400 mL of blood within 3 months prior to the screening. * Participation in a clinical drug study 30 days prior to present study. * Use of any other drugs within 2 weeks prior to the screening. * Subjects planning to give birth or donate sperm during the study or within 3 months after the study. * The partner of the subject is unwilling to take effective contraceptive measures. * Other unfavorable factors diagnosed by investigators.